A randomized, placebo‐controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER).

Saved in:
Bibliographic Details
Title: A randomized, placebo‐controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER).
Authors: Austin, Cary D.1 (AUTHOR) austin.cary@gene.com, Gonzalez Edick, Melissa1 (AUTHOR), Ferrando, Ronald E.1 (AUTHOR), Solon, Margaret1 (AUTHOR), Baca, Miriam1 (AUTHOR), Mesh, Kathryn1 (AUTHOR), Bradding, Peter2 (AUTHOR), Gauvreau, Gail M.3 (AUTHOR), Sumino, Kaharu4 (AUTHOR), FitzGerald, J. Mark5 (AUTHOR), Israel, Elliot6 (AUTHOR), Bjermer, Lief7 (AUTHOR), Bourdin, Arnaud8 (AUTHOR), Arron, Joseph R.1 (AUTHOR), Choy, David F.1 (AUTHOR), Olsson, Julie K.1 (AUTHOR), Abreu, Francis1 (AUTHOR), Howard, Monet1 (AUTHOR), Wong, Kit1 (AUTHOR), Cai, Fang1 (AUTHOR)
Source: Clinical & Experimental Allergy. Dec2020, Vol. 50 Issue 12, p1342-1351. 10p. 2 Diagrams, 3 Charts, 2 Graphs.
Database: Environment Complete
Full text is not displayed to guests.
Description
ISSN:09547894
DOI:10.1111/cea.13731